Alexandria Real Estate Reports Increased Losses, Slow Leasing in Q1

Why It Matters

The widening losses and rising vacancy signal mounting pressure on the life‑sciences real‑estate market, prompting investors to reassess exposure to a sector facing oversupply and policy headwinds.

Key Takeaways

• FFO fell 20% YoY to $295.9 million
• Leasing activity dropped 46% QoQ to 647,356 sq ft
• Development leases jumped 135% to 117,935 sq ft
• 2026 lease turnover forecast 747k sq ft, 45% vacancy
• Net loss widened to $358.9 million in Q1

Pulse Analysis

The life‑sciences REIT landscape is entering a period of correction as demand for laboratory space outpaces growth. Alexandria Real Estate Equities, once a bellwether for biotech real‑estate, now confronts an oversupplied market, heightened by a slowdown in research funding and a shift toward artificial‑intelligence projects that do not require traditional wet labs. Policy uncertainty, highlighted by the recent dismissal of the National Science Foundation’s advisory board, adds to investor wariness, making capital allocation to lab properties more scrutinized than in prior years.

Alexandria’s Q1 numbers illustrate the strain. Funds from operations slipped to $295.9 million, a 20% year‑over‑year decline, while net losses ballooned to $358.9 million, marking the deepest quarterly deficit on record. Leasing activity contracted sharply, with only 647,356 sq ft signed—down 46% from the previous quarter—and a projected 45% vacancy rate on 747,000 sq ft slated for turnover in 2026. However, the REIT’s development pipeline showed resilience, posting a 135% increase in new‑build leases to 117,935 sq ft, suggesting that developers are still betting on long‑term demand despite short‑term headwinds.

For investors, the data underscores a need to balance exposure to high‑growth biotech tenants with the reality of rising vacancy and declining cash flow. Strategies may include selective divestiture of underperforming assets, renegotiating lease terms to secure longer commitments, or pivoting toward mixed‑use facilities that can accommodate both lab and office functions. The broader market will watch how Alexandria navigates this downturn, as its actions could set a precedent for other life‑sciences REITs grappling with similar challenges.